89bio reports first quarter 2022 financial results and provides corporate update

- entrigue phase 2 trial of pegozafermin in severe hypertriglyceridemia (shtg) patients remains on track with topline data expected in the second quarter of 2022 -
ETNB Ratings Summary
ETNB Quant Ranking